Somnolence in Abbvie Inc Drugs

7 drug(s) with this reaction

8,824 total reports

Overview

Somnolence has been reported as an adverse reaction across 7 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 8,824 adverse event reports mention somnolence in connection with Abbvie Inc products.

This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with somnolence, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.

Abbvie Inc Drugs Reporting Somnolence

The following Abbvie Inc drugs have somnolence listed in their FDA adverse event reports, sorted by report count:

Other Reactions Reported for Abbvie Inc Drugs

In addition to somnolence, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:

PAINARTHRALGIADRUG INEFFECTIVECOVID 19RHEUMATOID ARTHRITISPAIN IN EXTREMITYFATIGUEFALLSURGERYHEADACHETHERAPY INTERRUPTEDPNEUMONIADEATHBACK PAINDIARRHOEAPERIPHERAL SWELLINGNAUSEAURINARY TRACT INFECTIONILLNESSNASOPHARYNGITIS

Frequently Asked Questions

Which Abbvie Inc drugs cause Somnolence?

7 drug(s) manufactured by Abbvie Inc have somnolence listed in their FDA adverse event reports: LEVOTHYROXINE SODIUM, DIVALPROEX SODIUM, FENOFIBRATE, PANCRELIPASE, ATOGEPANT, and others.

How many Somnolence reports are there for Abbvie Inc drugs?

There are a combined 8,824 reports of somnolence across 7 Abbvie Inc drug(s) in the FDA adverse event database.

Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.